YAP1 regulates OCT4 activity and SOX2 expression to facilitate self-renewal and vascular mimicry of stem-like cells

Stem Cells

Volumn 33, Issue 6, 2015, Pages 1705-1718

  Bora Singhal, Namrata ^a   Nguyen, Jonathan ^a   Schaal, Courtney ^a   Perumal, Deepak ^b   Singh, Sandeep ^c   Coppola, Domenico ^a   Chellappan, Srikumar ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c National Institute of Biomedical Genomics   (India)

Author keywords

Non small cell lung cancer; Self renewal; Side population cells; Transcriptional regulation; Vascular mimicry

Indexed keywords

OCTAMER TRANSCRIPTION FACTOR 4; TRANSCRIPTION FACTOR SOX2; VERTEPORFIN; PHOSPHOPROTEIN; POU5F1 PROTEIN, HUMAN; POU5F1 PROTEIN, MOUSE; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TRANSCRIPTION FACTOR SOX; YAP PROTEIN, MOUSE; YAP1 (YES-ASSOCIATED) PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER STEM CELL; CONTROLLED STUDY; EMBRYONIC STEM CELL; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; LUNG CANCER; MESENCHYMAL STEM CELL; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; PROTEIN DOMAIN; SEVERE COMBINED IMMUNODEFICIENCY; ANIMAL; CELL PROLIFERATION; CELL SELF-RENEWAL; CYTOLOGY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PHYSIOLOGY; TUMOR CELL LINE;

MUS;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SELF RENEWAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; NEOPLASTIC STEM CELLS; OCTAMER TRANSCRIPTION FACTOR-3; PHOSPHOPROTEINS; SOXB1 TRANSCRIPTION FACTORS;

EID: 84929755110     PISSN: 10665099     EISSN: 15494918     Source Type: Journal    
DOI: 10.1002/stem.1993     Document Type: Article

References (74)

1. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
2. Demicheli R, Biganzoli E, Boracchi P, et al., Recurrence dynamics does not depend on the recurrence site. Breast Cancer Res 2008; 10: R83.
3. Demicheli R, Fornili M, Ambrogi F, et al., Recurrence dynamics for non-small-cell lung cancer: Effect of surgery on the development of metastases. J Thorac Oncol 2012; 7: 723-730.
4. Senthi S, Lagerwaard FJ, Haasbeek CJ, et al., Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer: A retrospective analysis. Lancet Oncol 2012; 13: 802-809.
5. Seve P, Dumontet C,. Chemoresistance in non-small cell lung cancer. Curr Med Chem Anticancer Agents 2005; 5: 73-88.
6. Lara PN, Jr., Lau DH, Gandara DR., Non-small-cell lung cancer progression after first-line chemotherapy. Curr Treat Options Oncol 2002; 3: 53-58.
7. Patel P, Chen EI,. Cancer stem cells, tumor dormancy, and metastasis. Front Endocrinol (Lausanne) 2012; 3: 125.
8. Allan AL, Vantyghem SA, Tuck AB, et al., Tumor dormancy and cancer stem cells: Implications for the biology and treatment of breast cancer metastasis. Breast Dis 2006; 26: 87-98.
9. Giancotti FG,. Mechanisms governing metastatic dormancy and reactivation. Cell 2013; 155: 750-764.
10. Lee N, Barthel SR, Schatton T,. Melanoma stem cells and metastasis: Mimicking hematopoietic cell trafficking? Lab Invest 2014; 94: 13-30.
11. Singh S, Chellappan S,. Lung cancer stem cells: Molecular features and therapeutic targets. Mol Aspects Med 2014; 39: 50-60.
12. Visvader JE, Lindeman GJ,. Cancer stem cells in solid tumours: Accumulating evidence and unresolved questions. Nat Rev Cancer 2008; 8: 755-768.
13. Ricci-Vitiani L, Pallini R, Biffoni M, et al., Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 2010; 468: 824-828.
14. Chiao MT, Yang YC, Cheng WY, et al., CD133+ glioblastoma stem-like cells induce vascular mimicry in vivo. Curr Neurovasc Res 2011; 8: 210-219.
15. Kaur S, Bajwa P,. A 'tete-a tete' between cancer stem cells and endothelial progenitor cells in tumor angiogenesis. Clin Transl Oncol 2014; 16: 115-121.
16. Fan YL, Zheng M, Tang YL, et al., A new perspective of vasculogenic mimicry: EMT and cancer stem cells (Review). Oncol Lett 2013; 6: 1174-1180.
17. Alamgeer M, Peacock CD, Matsui W, et al., Cancer stem cells in lung cancer: Evidence and controversies. Respirology 2013; 18: 757-764.
18. Jiang F, Qiu Q, Khanna A, et al., Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol Cancer Res 2009; 7: 330-338.
19. Sullivan JP, Spinola M, Dodge M, et al., Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling. Cancer Res 2010; 70: 9937-9948.
20. Zhang WC, Shyh-Chang N, Yang H, et al., Glycine decarboxylase activity drives non-small cell lung cancer tumor-initiating cells and tumorigenesis. Cell 2012; 148: 259-272.
21. Singh S, Trevino J, Bora-Singhal N, et al., EGFR/Src/Akt signaling modulates Sox2 expression and self-renewal of stem-like side-population cells in non-small cell lung cancer. Mol Cancer 2012; 11: 73.
22. Singh S, Bora-Singhal N, Kroeger J, et al., betaArrestin-1 and Mcl-1 modulate self-renewal growth of cancer stem-like side-population cells in non-small cell lung cancer. PLoS One 2013; 8: e55982.
23. Piccolo S, Cordenonsi M, Dupont S,. Molecular pathways: YAP and TAZ take center stage in organ growth and tumorigenesis. Clin Cancer Res 2013; 19: 4925-4930.
24. Halder G, Camargo FD,. The hippo tumor suppressor network: From organ size control to stem cells and cancer. Cancer Res 2013; 73: 6389-6392.
25. Hao J, Zhang Y, Jing D, et al., Role of Hippo signaling in cancer stem cells. J Cell Physiol 2014; 229: 266-270.
26. Harvey KF, Zhang X, Thomas DM,. The Hippo pathway and human cancer. Nat Rev Cancer 2013; 13: 246-257.
27. Wang Y, Dong Q, Zhang Q, et al., Overexpression of yes-associated protein contributes to progression and poor prognosis of non-small-cell lung cancer. Cancer Sci 2010; 101: 1279-1285.
28. Zhou Z, Hao Y, Liu N, et al., TAZ is a novel oncogene in non-small cell lung cancer. Oncogene 2011; 30: 2181-2186.
29. Yu T, Bachman J, Lai ZC,. Evidence for a tumor suppressor role for the large tumor suppressor genes LATS1 and LATS2 in human cancer. Genetics 2013; 195: 1193-1196.
30. Zhang N, Bai H, David KK, et al., The Merlin/NF2 tumor suppressor functions through the YAP oncoprotein to regulate tissue homeostasis in mammals. Dev Cell 2010; 19: 27-38.
31. Ramos A, Camargo FD,. The Hippo signaling pathway and stem cell biology. Trends Cell Biol 2012; 22: 339-346.
32. Lin XY, Zhang XP, Wu JH, et al., Expression of LATS1 contributes to good prognosis and can negatively regulate YAP oncoprotein in non-small-cell lung cancer. Tumour Biol 2014; 35: 6435-6443.
33. Director's Challenge Consortium for the Molecular Classification of Lung A et al. Gene expression-based survival prediction in lung adenocarcinoma: A multi-site, blinded validation study. Nat Med 2008; 14: 822-827.
34. Lian I, Kim J, Okazawa H, et al., The role of YAP transcription coactivator in regulating stem cell self-renewal and differentiation. Genes Dev 2010; 24: 1106-1118.
35. Sun B, Zhang S, Zhang D, et al., Vasculogenic mimicry is associated with high tumor grade, invasion and metastasis, and short survival in patients with hepatocellular carcinoma. Oncol Rep 2006; 16: 693-698.
36. Millimaggi D, Mari M, D'Ascenzo S, et al., Vasculogenic mimicry of human ovarian cancer cells: Role of CD147. Int J Oncol 2009; 35: 1423-1428.
37. Qayum N, Muschel RJ, Im JH, et al., Tumor vascular changes mediated by inhibition of oncogenic signaling. Cancer Res 2009; 69: 6347-6354.
38. Upile T, Jerjes W, Radhi H, et al., Vascular mimicry in cultured head and neck tumour cell lines. Head Neck Oncol 2011; 3: 55.
39. Wang R, Chadalavada K, Wilshire J, et al., Glioblastoma stem-like cells give rise to tumour endothelium. Nature 2010; 468: 829-833.
40. Soda Y, Marumoto T, Friedmann-Morvinski D, et al., Transdifferentiation of glioblastoma cells into vascular endothelial cells. Proc Natl Acad Sci USA 2011; 108: 4274-4280.
41. Brown DM, Michels M, Kaiser PK, et al., Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology 2009; 116: 57-65.
42. Belzacq AS, Jacotot E, Vieira HL, et al., Apoptosis induction by the photosensitizer verteporfin: Identification of mitochondrial adenine nucleotide translocator as a critical target. Cancer Res 2001; 61: 1260-1264.
43. Liu-Chittenden Y, Huang B, Shim JS, et al., Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. Genes Dev 2012; 26: 1300-1305.
44. Tomioka M, Nishimoto M, Miyagi S, et al., Identification of Sox-2 regulatory region which is under the control of Oct-3/4-Sox-2 complex. Nucleic Acids Res 2002; 30: 3202-3213.
45. Chew JL, Loh YH, Zhang W, et al., Reciprocal transcriptional regulation of Pou5f1 and Sox2 via the Oct4/Sox2 complex in embryonic stem cells. Mol Cell Biol 2005; 25: 6031-6046.
46. Miyagi S, Nishimoto M, Saito T, et al., The Sox2 regulatory region 2 functions as a neural stem cell-specific enhancer in the telencephalon. J Biol Chem 2006; 281: 13374-13381.
47. Söderberg O, Leuchowius KJ, Gullberg M, et al., Characterizing proteins and their interactions in cells and tissues using the in situ proximity ligation assay. Methods 2008; 45: 227-232.
48. Söderberg O, Gullberg M, Jarvius M, et al., Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nat Methods 2006; 3: 995-1000.
49. Smith MA, Hall R, Fisher K, et al., Annotation of human cancers with EGFR signaling-associated protein complexes using proximity ligation assays. Sci Signal 2015; 8: ra4.
50. Komuro A, Nagai M, Navin NE, et al., WW domain-containing protein YAP associates with ErbB-4 and acts as a co-transcriptional activator for the carboxyl-terminal fragment of ErbB-4 that translocates to the nucleus. J Biol Chem 2003; 278: 33334-33341.
51. Chen HI, Sudol M,. The WW domain of Yes-associated protein binds a proline-rich ligand that differs from the consensus established for Src homology 3-binding modules. Proc Natl Acad Sci USA 1995; 92: 7819-7823.
52. Yagi R, Chen LF, Shigesada K, et al., A WW domain-containing yes-associated protein (YAP) is a novel transcriptional co-activator. EMBO J 1999; 18: 2551-2562.
53. Xu H, Wang W, Li C, et al., WWP2 promotes degradation of transcription factor OCT4 in human embryonic stem cells. Cell Res 2009; 19: 561-573.
54. Mani SA, Guo W, Liao MJ, et al., The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133: 704-715.
55. Xin L, Lawson DA, Witte ON,. The Sca-1 cell surface marker enriches for a prostate-regenerating cell subpopulation that can initiate prostate tumorigenesis. Proc Natl Acad Sci USA 2005; 102: 6942-6947.
56. Wang Y, Dong Q, Zhang Q, et al., Overexpression of yes-associated protein contributes to progression and poor prognosis of non-small-cell lung cancer. Cancer Sci 2010; 101: 1279-1285.
57. Lamar JM, Stern P, Liu H, et al., The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain. Proc Natl Acad Sci USA 2012; 109: E2441-2450.
58. Das S, Levasseur D,. Transcriptional regulatory mechanisms that govern embryonic stem cell fate. Methods Mol Biol 2013; 1029: 191-203.
59. Sorrentino G, Ruggeri N, Specchia V, et al., Metabolic control of YAP and TAZ by the mevalonate pathway. Nat Cell Biol 2014; 16: 357-366.
60. Yu FX, Zhao B, Panupinthu N, et al., Regulation of the Hippo-YAP pathway by G-protein-coupled receptor signaling. Cell 2012; 150: 780-791.
61. Kirschmann DA, Seftor EA, Hardy KM, et al., Molecular pathways: Vasculogenic mimicry in tumor cells: Diagnostic and therapeutic implications. Clin Cancer Res 2012; 18: 2726-2732.
62. Seo E, Basu-Roy U, Gunaratne PH, et al., SOX2 regulates YAP1 to maintain stemness and determine cell fate in the osteo-adipo lineage. Cell Rep 2013; 3: 2075-2087.
63. Liu K, Lin B, Zhao M, et al., The multiple roles for Sox2 in stem cell maintenance and tumorigenesis. Cell Signal 2013; 25: 1264-1271.
64. Sarkar A, Hochedlinger K,. The sox family of transcription factors: Versatile regulators of stem and progenitor cell fate. Cell Stem Cell 2013; 12: 15-30.
65. Chou YT, Lee CC, Hsiao SH, et al., The emerging role of SOX2 in cell proliferation and survival and its crosstalk with oncogenic signaling in lung cancer. Stem Cells 2013; 31: 2607-2619.
66. Justilien V, Walsh MP, Ali SA, et al., The PRKCI and SOX2 oncogenes are coamplified and cooperate to activate Hedgehog signaling in lung squamous cell carcinoma. Cancer Cell 2014; 25: 139-151.
67. Liu K, Jiang M, Lu Y, et al., Sox2 cooperates with inflammation-mediated Stat3 activation in the malignant transformation of foregut basal progenitor cells. Cell Stem Cell 2013; 12: 304-315.
68. Chen Y, Shi L, Zhang L, et al., The molecular mechanism governing the oncogenic potential of SOX2 in breast cancer. J Biol Chem 2008; 283: 17969-17978.
69. Wilson M, Koopman P,. Matching SOX: Partner proteins and co-factors of the SOX family of transcriptional regulators. Curr Opin Genet Dev 2002; 12: 441-446.
70. Beyer TA, Weiss A, Khomchuk Y, et al., Switch enhancers interpret TGF-beta and Hippo signaling to control cell fate in human embryonic stem cells. Cell Rep 2013; 5: 1611-1624.
71. Sudol M, Shields DC, Farooq A,. Structures of YAP protein domains reveal promising targets for development of new cancer drugs. Semin Cell Dev Biol 2012; 23: 827-833.
72. Shao DD, Xue W, Krall EB, et al., KRAS and YAP1 converge to regulate EMT and tumor survival. Cell 2014; 158: 171-184.
73. Kalluri R, Weinberg RA,. The basics of epithelial-mesenchymal transition. J Clin Invest 2009; 119: 1420-1428.
74. Lau AN, Curtis SJ, Fillmore CM, et al., Tumor-propagating cells and Yap/Taz activity contribute to lung tumor progression and metastasis. EMBO J 2014; 33: 468-481.